From: The human microglial HMC3 cell line: where do we stand? A systematic literature review
| Markers | Original characterization | CHME3 cells | HMC3 cells | References | |||
|---|---|---|---|---|---|---|---|
| Resting | Stimulated | Resting | Stimulated | Resting | Stimulated | ||
| Pro-inflammatory molecules | |||||||
| IL-6 | 1553 ± 142 |
IL-1α: > 2500 LPS: 2110 ± 111 | 20–950/sizable amount |
LPS: 2–4 fold ↑ IL-1β: 50 fold ↑ IFNγ: modest ↑ IL-1β + IFNγ: additional ↑ Aβ1–40: 2–12 fold ↑ Aβ1–40 + IFNγ: no- additional ↑ Aβ1–42: no effect α-MSH: ↑ EPA: ↑ HCV NS3: ↑ | Sizable amount /(mRNA level) |
HIV-vector: ↑ HIV-U937: ↑ | [17, 20, 21, 30, 36, 37, 40, 43, 47, 48] |
| TNFα | ND | ND | 4–8/ND |
Aβ1–40: no effect Aβ1–42: modest ↑ HCV NS3: ↑ | (mRNA level) | [17, 21, 37, 40, 43, 44, 47] | |
| IL-1α | ND | Aβ1–40: no effect | [47] | ||||
| IL-1β | ND |
Aβ1–40: no effect HCV NS3: ↑ | ND /(mRNA level) | [21, 30, 40, 47] | |||
| Caspase-1 | ND | Aβ1–40: no effect | [47] | ||||
| IL-12 | LPS:↑ | [52] | |||||
| IFNγ | LPS:↑ | ND | [30, 52] | ||||
| iNOS | 16% of cells (positive immunoreactivity) | (mRNA level) | [20, 36] | ||||
| ROS | Sizable amount | HIV TAT-C protein: modest ↑ | [20, 21] | ||||
| Antinflammatory molecules | |||||||
| IL-4 | ND | [30] | |||||
| IL-10 | 5,4 | Aβ1–42: no effect | ND | [30, 43] | |||
| TGFβ1 | ~ 8 | (mRNA level) | [20, 37] | ||||
| TGFβ2 | ~ 100 | [37] | |||||
| Chemokines | |||||||
| CCL2 | HIV-U937: ↑ | [30] | |||||
| CCL5 | Sizable amount |
HIV-vector: ↑ HIV-U937: ↑ | [30] | ||||
| IL-8 | HCV NS3: ↑ | [40] | |||||
| CXCL10 |
HIV-vector: ↑ HIV-U937: ↑ | [30] | |||||